After Vaccine Recalculation, AstraZeneca Looks To Move On But Likely Faces Extra US FDA Scrutiny

 
• By Andrew McConaghie

Results for AstraZeneca’s COVID shot edge down to 76% after data and safety monitoring board raised alarm about outdated figures.

AZ Vaccines
AZ expects to file with the US FDA in the coming weeks, and is likely to face extra questions about its safety and efficacy data.

More from Clinical Trials

More from R&D